U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Honeywell International (HON) PT Raised to $240 at BofA Securities
November 13, 2024 10:15 AM ESTBofA Securities analyst Andrew Obin raised the price target on Honeywell International (NASDAQ: HON) to $240.00 (from $220.00) while maintaining a Neutral rating.
The analyst comments "On 11/12, Elliott Investment Management disclosed ownership of $5bn+ worth of Honeywell shares (equivalent to ~3% of shares). Elliotts letter... More
Honeywell International (HON) PT Raised to $253 at RBC Capital
November 13, 2024 6:45 AM ESTRBC Capital analyst Deane Dray raised the price target on Honeywell International (NASDAQ: HON) to $253.00 (from $213.00) while maintaining a Sector Perform rating.
The analyst comments "Addressing HONs chronic underperformance, activist Elliott Management on Nov-12 announced a +$5 bil/3.5% stake in Sector Perform-rated... More
Leerink Partners Reiterates Market Perform Rating on Rapt Therapeutics (RAPT)
November 12, 2024 4:08 PM ESTLeerink Partners analyst Thomas Smith reiterated a Market Perform rating and $2.00 price target on Rapt Therapeutics (NASDAQ: RAPT).
The analyst comments "Bottom Line: RAPT reported 3Q24 financial results following the company's decision to terminate development of zelnecirnon (RPT193, oral CCR4 antagonist) based on recent FDA feedback suggesting there was no viable path forward for this program (see our note HERE).... More
Stifel Downgrades Rapt Therapeutics (RAPT) to Hold
November 12, 2024 4:04 PM ESTStifel analyst Alex Thompson downgraded Rapt Therapeutics (NASDAQ: RAPT) from Buy to Hold with a price target of $2.00 (from $7.00).
The analyst comments "We are downgrading RAPT to Hold following the recent Zelnecirnon program termination (LINK). RAPT discontinued the program following FDA feedback suggesting... More
Barclays on Honeywell International (HON) and Elliot Report: 'Activist involvement not a surprise'
November 12, 2024 10:52 AM ESTBarclays analyst Julian Mitchell reiterated an Overweight rating and $229.00 price target on Honeywell International (NASDAQ: HON).
The analyst comments "Following press reports (see here) that Elliott has taken a $5bn stake in HON (this has been confirmed in a letter from Elliott), we provide an update on our SoTPs below. These on average yield a share price of $251, with a FCF SoTP of $267. We do not think this news is a surprise (we do not think HON will be surprised either), as: 1. We had highlighted in our post-Q3 HON report that... More
Albemarle (ALB) PT Raised to $133 at RBC Capital
November 12, 2024 6:26 AM ESTRBC Capital analyst Arun Viswanathan raised the price target on Albemarle (NYSE: ALB) to $133.00 (from $108.00) while maintaining a Outperform rating.
The analyst comments "Overall, ALB had a decent 3Q with dd% growth in Energy Storage, Specialties earnings inflecting positive y/y,... More
Deutsche Bank on Tesla (TSLA): 'To the victor belong the spoils'
November 12, 2024 5:13 AM ESTDeutsche Bank analyst Edison Yu reiterated a Buy rating and $295.00 price target on Tesla (NASDAQ: TSLA).
The analyst comments "Since election night, Tesla has added >$300bn of market cap, crossing the $1 trillion level for the first time since early 2022 (+39% vs. NASDAQ +5%). Similarly, we suspect... More
